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Joseph Pidala,1,2 Claudio Anasetti1,2Acute graft-versus-host disease (aGVHD) is a major cause of hematopoietic cell transplant (HCT) associated
morbidity andmortality. Thosewho fail first-line therapywith$1mg/kgof glucocorticoids achieve limitedcom-
plete responses to salvage agents, and suffer inferior outcomes compared to those who respond to glucocor-
ticoids. The literature to date in salvage therapy for refractory aGVHD suffers from a number of methodologic
limitations, and the near absence of data on comparative effectiveness of alternative salvage agents limits con-
clusions and application to clinical practice. This review examines the current literature on salvage therapy for
glucocorticoid-refractory aGVHD, identifies barriers to progress in the field, calls for consensus in definitions
and response criteria in the conduct of refractory aGVHD trials, and explores the scientific and therapeutic
implications of molecular insights into glucocorticoid responsiveness realized in allied investigation.
Biol Blood Marrow Transplant 16: 1504-1518 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Glucocorticoid-refractory, Acute graft-versus-host disease, Allogeneic hematopoietic cell
transplantationINTRODUCTION
Acute graft-versus-host disease (aGVHD) poses
a significant threat of morbidity and mortality follow-
ing allogeneic hematopoietic cell transplantation
(HCT). The syndrome remains a major obstacle to
otherwise potentially curative therapy for hematopoi-
etic disorders. The underlying pathophysiology is
complex, and is thought to consist of several interre-
lated phases [1-4]. The incidence of aGVHD varies
across studies, and according to patient, transplant
regimen, and aGVHD prophylaxis conditions, but
has generally been reported in the range of 30% to
50%. Risk factors for the development of aGVHD
have most consistently been reported as older age of
the recipient and donor/recipient HLA disparity;
others include male recipient/female donor pairs,
conditioning regimen, condition requiring HCT,
race, use of peripheral blood stem cells, reduced
performance status, and cytomegalovirus (CMV)
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6/j.bbmt.2010.01.007First-line therapy for aGVHD has historically in-
cluded $1 mg/kg of glucocorticoids for variable treat-
ment duration. However, complete response to this
therapy has only approached 20% to 50%, and those
without complete response suffer poor long-term out-
comes because of refractory aGVHD, as well as toxicity
from and opportunistic infections incurred with salvage
immunosuppressive therapy. As well, the primary treat-
ment of aGVHDis empiric, and the largest series todate
examining primary therapy with glucocorticoids have
not produced consistent predictors of response [10-12].
However, most data suggest decreasing likelihood of
complete response to primary therapy with increasing
aGVHD grade, as well as with increasing number of
organs involved. Data consistently support, however,
inferior survival in those who fail to respond to
primary therapy.
There are many challenges in the interpretation of
literature examining salvage therapies for glucocorti-
coid-refractory aGVHD, and subsequently to the ra-
tional application of these agents in clinical practice.
First, there is limited consensus in regard to the defini-
tion of glucocorticoid refractoriness, with variation in
both the dose and duration of first-line glucocorticoid
therapy utilized, as well as the time allotted to assess
treatment response. Second, outside of a singular ran-
domized controlled trial [13], conclusions regarding
the comparative effectiveness of individual salvage
agents are limited by study design; these consist almost
entirely of retrospective series, or alternatively early
phase trials with small sample sizes. Importantly, the
intention of many of these early phase trials has been
Biol Blood Marrow Transplant 16:1504-1518, 2010 1505Glucocorticoid-Refractory Acute Graft-versus-Host Diseaseto examine the safety and activity of these agents antic-
ipating their translation to other phases of GVHD
prophylaxis and treatment. Next, the therapeutic im-
pact of a salvage agent in these series is often difficult
to discern, as many subjects have been either previ-
ously treated with other salvage therapy, or go on to re-
ceive additional salvage agents in succession after the
agent of interest. This is further circumscribed by
the fact that there is limited consensus across trials in
the time allotted to assess response after the salvage
agent of interest. Accordingly, there is little evidence
that suggests the superiority of 1 agent over another,
and investigation and clinical practice in the manage-
ment of glucocorticoid-refractory aGVHD remains
disjointed and transplant center-dependent. Finally,
efforts to date in refractory aGVHD are reactive in na-
ture, target specific facets of the heterogeneous and re-
dundant aGVHD cascade in isolation, and have
ultimately produced limited durable responses and
inferior long-term survival compared to those with ste-
roid responsive disease. A series of major, unexamined
questions in this field beg a better understanding of
the biology of steroid-refractoriness, and conversely,
responsiveness.MECHANISMS OF GLUCOCORTICOID
RESISTANCE
As reviewed by Barnes and Adcock [14], glucocorti-
coid resistance has been clinically characterized in sev-
eral inflammatory conditions, including asthma,
rheumatoid arthritis, systemic lupus erythematosis, ul-
cerative colitis, and Crohn’s disease. As well, circulating
lymphocytes from such subjects demonstrate reduced
suppressionofproliferationandcytokine elaborationaf-
ter treatment with glucocorticoids compared to those
with glucocorticoid responsive disease, suggesting
a systemic abnormality in glucocorticoid responsiveness
[14-17]. Basic work has elucidated the major mecha-
nisms of glucocorticoid action, including activation of
anti-inflammatory genes, as well as suppression of
activated inflammatory genes [18,19], and molecular
mechanisms of glucocorticoid refractoriness have been
determined. These include the following: alteration of
glucocorticoid receptor (GR) binding affinity by
phosphorylation mediated by p38 MAP (mitogen
activated protein)-kinase, JAK3 (janus kinase 3), and
JNK (c-Jun N-terminal kinase) [20]; decreased expres-
sion of MKP-1 (MAP-kinase phosphatase), which nor-
mally exerts an inhibitory effect on MAP-kinase and
its associated expression of inflammatory genes [21]; in-
hibition of the GR by nitrosylation or ubiquitinylation
[22]; increased expression of GRb, which competes
with the active GRa for binding to glucocorticoid re-
sponsive elements (GRE) [23]; activationofAP1 (activa-
tor protein 1), which binds to the GR and prevents itsinteraction with GRE [24]; abnormal histone acetyla-
tion [25]; decreased HDAC-2 (histone deacetylase 2)
expression and activity, which reverses acetylation
mediated by NFkb [17]; increased expression of P-
glycoprotein, leading to transport of glucocorticoids
out of the cell [26]; and increased expression of MIF
(macrophage migration inhibitory factor), which in-
hibits the anti-inflammatory effect mediated by MKP-
1 [27]. In addition, early work has demonstrated that
gene expression profiling in human peripheral blood
mononuclear cells (PBMC) can predict glucocorticoid
sensitivity in asthma patients [28]. These molecular
insights from related inflammatory disorders with glu-
cocorticoid resistancemay have relevance in glucocorti-
coid-refractory aGVHD.However, to date, the biology
of steroid refractoriness in the treatment of aGVHDhas
not been examined.SALVAGE THERAPY FOR
GLUCOCORTICOID-REFRACTORYAGVHD
Antilymphocyte Antibody and Immunotoxin
Therapies
Antithymocyte globulin
Based on the understanding of alloreactive donorT
cells’ role in effecting aGVHD, antithymocyte globu-
lin (ATG) has been studied as a salvage therapy for glu-
cocorticoid-refractory aGVHD(Table 1).Toxicity has
been reported to include allergic manifestations, fever,
hypotension, and anaphylaxis, largely avoided by pre-
medication. Overall response rates (ORRs) range
from 30% to 56%, and complete response (CR) rates
approach 8% to 36% [29-34]. In most reports,
a greater proportion achieve complete remission of
skin involvement compared to other manifestations
[29,31,32,34]. Long-term survival is limited, with
major threats after treatment including refractory
aGVHD, infectious morbidity, and mortality, as well
as Ebstein Barr virus (EBV)-driven posttransplant
lymphoproliferative disease (PTLD) [35]. Those fail-
ing to respond to ATG suffer worse outcomes [29,30].
ABX-CBL (anti-CD147)
ABX-CBL targets the CD147 antigen, which is
expressed on activated T and B lymphocytes as well
as antigen-presenting cells (APCs), and induces com-
plement-mediated lysis. In a phase I-II prospective
trial, ABX-CBL induced an ORR of 51%, and com-
plete response in 25%. Overall survival (OS) at 450
days was 29%, with the majority of deaths resulting
from refractory aGVHD or multiorgan failure [36].
This agent was compared in a randomized phase II/
IIImulticenter trial againstATG for secondary therapy
of refractory aGVHD. Powered to detect a 20% im-
provement in 180-day OS compared ATG, the results
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Table 1. (Continued )
Agent Study Methods n Refractory Definition Treatment
Overall
Response Complete Response CR by Organ CR by Grade Overall Survival
Predictors
of CR
Predictors
of OS
Przepiorka
et al., 2000
Phase II trial 43 total persisting for 3
days while
receiving $ 2
mg/kg/d steroids
or developing
while on $ 1
mg/kg/d steroids
Cohort 1:
(n 5 24) 1
mg/kg on days
1, 8, 15, 22, and 29.
Cohort 2: (n 5 19)
1 mg/kg on days
1, 4, 8, 15, and 22.
ORR (all patients): 51%
(response by day 43)
Cohort 1:
CR: 29%
Cohort 2:
CR: 47%
Skin: 20/37 (54%)
Liver: 2/12 (17%)
GI: 10/27 (37%)
Grade I/II:
10/23 (43%)
Grade III/IV:
6/20 (30%)
Cohort 1:
120 day survival: 29%
Cohort 2:
120 day survival: 53%
organ involvement
Willenbacher et al.,
2001
Prospective
trial
12 unresponsive to
steroid $ 2
mg/kg given for
$ 3 d
1 mg/kg day 1-2
(or 1-5), then
7, 14 and 21
ORR: 8/12
(by day 28)
CR: 1/12 2/12 alive 458 and 459
d post
daclizumab treatment
Bordigoni et al., 2006 Phase II trial 62 Steroid refractory 1 mg/kg i.v. on
days 1, 4, 8, 15
and 22
ORR: 90.1%
(by day 30)
CR: 68.8% CR: Isolated skin
(73.7%), or GI
(90.5%) vs.
multiorgan
involvement
(42.9%)
Stage I/II skin:
CR 72.7%
Stage III/IV skin:
CR 33.3%
4 year EFS: 54.6% EFS: Grade $ III
aGVHD, $ 2
involved organs at
baseline, and
patient age >18 years
Perales et al., 2007 Retrospective 57 Progression or
failure to respond
after 7 days of
steroid therapy,
or flare upon taper
1 mg/kg i.v. days
1, 8, 15, 22
and 29 (n59),
or days 1, 4, 8,
15, 22 (n548).
15 patients had
additional weekly
doses
ORR: 54%
(by day 43)
CR: n/a Skin: 64%
GI: 46%
Liver: 20%
Median f/u 98 months:
25%
organ involvement,
donor relation,
pediatric patients
grade III/IV aGVHD,
adult vs. pediatric
Enlimomab Pinana et al., 2006 Retrospective 40 Steroid refractory 11 mg/d for 3
consecutive days,
followed by 5.5
mg/d for 7
consecutive days
and then 5.5 mg
every other day
for 5 doses
ORR: 23/40 (58%) CR: 15/40 (38%) 1 year OS:
Responders: 59%
Non-responders: 0%
no GI involvement response to therapy
Basiliximab Massenkeil
et al., 2002
Prospective
trial
17 resistant to steroid
therapy of $ 2
mg/kg/day for
$ 3 days
20 mg on 2
consecutive days;
repeated on
day 8 in cases of
persistent GVHD
median of four
infusions (range
1–12)
ORR: 12/17 (71%) CR: 9/17 (53%) Skin: 9/15 (60%)
GI: 8/11 (73%)
Liver: 3/4 (75%)
II 1/3
(30%)
III 8/12 (67%)
IV 0/2 (0%)
Median follow up 157
days: OS 53%
Schmidt-Hieber et al.,
2005
Phase II trial 23 Progressive or unchanged
after
3 days of 2mg/kg
steroids
20 mg on days
1 and 4
ORR: 19/23 (82.5%) CR: 4/23 (17.5%) Skin: 4/22 (18%)
GI: 3/12 (56%)
Liver: 1/7 (14%)
II 3/11 (27%)
III 1/12 (8%)
IV none
Denileukin
diftitox
(Ontak)
Ho et al., 2004 Phase I trial 30 no improvement
after 2 weeks
on corticosteroids
($ 1 mg/kg), progression of
GVHD after 1
week on corticosteroids,
or GVHD flare after
taper unresponsive to
steroids
9 mg/kg IVon days 1 and 15
(n57)
9 mg/kg IV on days 1, 3, 5,
15, 17, and 19 (n518)
9 mg/kg IV on days 1 to 5
and 15 to 19 (n55)
(overall sample)
ORR: 71%
(by day 29)
(overall sample)
CR: 33%
Skin: 7/16 (44%)
GI: 9/16 (56%)
Liver: 1/4 (25%)
II: 1/8 (13%)
III: 5/13 (38%)
IV: 2/3 (67%)
At median f/u of 7.2
months: 33% alive
achievement
of CR vs. not
GVHD indicates graft-versus-host disease; ATG, antithymocyte globulin; CR, complete resonse; PR, partial response; GI, gastrointestinal; CML, chronic myelogenous leukemia; mo, month; ORR, overall response rate.
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rates (56% versus 57%, P5 .91), and demonstrated in-
ferior 180-day OS (35% versus 45%) in the ABX-CBL
arm (Table 1) [13].
Anti-CD3 antibodies (OKT3, Visilizumab)
Antibodies targeting the T cell antigen CD3 have
demonstrated activity in glucocorticoid-refractory
aGVHD (Table 1). Early work from Hebart et al.
[37] demonstrated the clinical activity of anti-CD3 an-
tibodies OKT3 and BMA031, and the relationship be-
tween induction of CD3 lymphopenia and resolution
of aGVHD. Carpenter et al. [38] examined the role
of the humanized non-FcR-binding anti-CD3 anti-
body, visilizumab, in the treatment of refractory
aGVHD. Visilizumab demonstrated striking activity
in a phase I study, with 6/9 in the single dose (3 mg/
m2) group achieving complete remission. EBV reacti-
vation was notable, and PTLD developed in 2 cases,
which was thereafter avoided by EBVDNA titer mon-
itoring and preemptive therapy with rituximab. In
a subsequent multicenter phase II trial, ORR was
32%, CR 14%, and 180-day survival was 32%; these
results in the phase II trial may have been explained
by differences in patient characteristics: the phase II
trial had older median age, a greater proportion with
bilirubin $3, and 32% with Visilizumab as third-line
therapy after mycophenolate mofetil [39].
Anti-CD5—ricin conjugate
Therapy directed at the CD5 antigen on mature T
cells has been examined in glucocorticoid refractory
aGVHD (Table 1). Byers et al. [40] demonstrated
the clinical activity of H65-RTA, a CD5-specific
monoclonal antibody conjugated to the ricin cytotoxic
enzyme, in a phase I-II trial; complete responses were
seen in 9 of 32 evaluable patients.
Anti-CD52 (Alemtuzumab)
Alemtuzumab is a humanized monoclonal anti-
body against the CD52 antigen, which is expressed
on T and B lymphocytes, as well as monocytes and
dendritic cells. Several case reports have suggested its
activity in refractory aGHVD [41,42]. Two small
prospective trials have examined the efficacy of
alemtuzumab in the management of steroid refractory
aGVHD (Table 1). Gomez-Almaguer et al. [43] re-
ported an ORR of 83%, CR of 33%, and median sur-
vival of not reached, 8 months, and 2 months, for CR,
partial response (PR), and no response, respectively.
These encouraging findings were not supported by
Martinez et al. [44], where response rates were lower
(ORR 5/10, CR 2/10), and all of the 10 patients died
at a median of 40 days (range: 4 to 88 days) from
GVHD (n5 4), GVHD and liver ormultiorgan failure
(n 5 2), GVHD and invasive fungal infection (n 5 1),bacterial sepsis (n 5 1), invasive fungal infection (n 5
1), or relapse (n5 1). This discrepancy in aGVHD re-
sponse and survival may in part be explained by the
subjects in Martinez et al. [44] having older age (me-
dian 57 years [range: 19 to 65 years] versus 37 years
[range: 1 to 59 years]) and more advanced GVHD
(grade III-IV, 100% versus 56%) compared to those
in Gomez-Almaguer et al. [43]. In both studies, pneu-
mocystis, fungal, and viral prophylaxis were required,
and monitoring was done for CMV with preemptive
therapy at reactivation.
Anti-CD25 antibodies (Daclizumab, Enlimomab,
Basiliximab)
Daclizumab, a humanized monoclonal IgG1 anti-
body, binds the alpha subunit of the IL-2 receptor
(CD25), and thereby blocks IL-2 signaling and T cell
proliferation. Several moderate-sized prospective trials
[45-48] and a single institution retrospective analysis
have examined its efficacy in the treatment of
glucocorticoid refractory aGVHD [49]. ORRs have
generally ranged from 40% to 67%, with CR rates of
8% to 47%. However, Bordigoni et al. [45,47-49]
reported an ORR of 90% and CR rate of 69%. These
disparate findings may be explained by the relatively
milder grade distribution at the time of daclizumab
therapy in this trial, in which only 34% had equal to or
more than grade III aGVHD. Consistent across these
studies, response rates are significantly greater in skin
involvement compared to either other organ or
multiorgan involvement. Survival reported after
daclizumab therapy for refractory aGVHD is limited.
Despite standard infectious prophylaxis, infectious
death remains a concern after this therapy; the
proportion of deaths attributed to infectious causes has
varied from 11% to 60% [45-49]. Activity in refractory
aGVHD has also been demonstrated with the anti-IL2
receptor antibody, enlimomab [50], as well as basilixi-
mab (Table 1) [51,52]. The use of anti-CD25
therapies poses a risk of depleting CD41CD251
regulatory T cells; clinical evidence to date from allied
disciplines has demonstrated conflicting effects,
including no effect [53], transient depletion [54], or de-
pletion of regulatory T cells after anti-CD25 antibody
therapy [55,56].
Denileukin diftitox (Ontak)
Denileukin diftitox is a recombinant fusion protein
comprised of human interleukin-2 complexed with the
membrane translocation and catalytic domains of the
diphtheria toxin. It is thought to have selective effect
on activated T lymphocytes because of their upregula-
tion of the IL-2 receptor. This toxin enters the cell and
leads to cessation of protein synthesis and apoptosis. In
a phase I trial, denileukin diftitox demonstrated
marked activity in refractory aGVHD (Table 1).
1510 Biol Blood Marrow Transplant 16:1504-1518, 2010J. Pidala and C. AnasettiPrimarily self-limited transaminitis was the most com-
mon toxicity, occurring in 26% [57].
Anitumor Necrosis Factor Alpha (TNFa)
Therapy
Infliximab and etanercept
TNFa has been demonstrated to be involved in key
aspects of aGVHD pathogenesis, and clinical observa-
tions have documented elevated levels in those with
aGVHD. As well, anti-TNFa therapy has activity in
inflammatory bowel disease, further suggesting the
rationale for targeting this inflammatory cytokine in
intestinal manifestations of aGVHD. Infliximab is
a murine-human chimeric monoclonal antibody that
binds both the soluble subunit and membrane-bound
precursor of TNFa. Case reports [58] and larger single
institution retrospective series [59-61] have described
the efficacy of infliximab for the treatment of
glucocorticoid-refractory aGVHD (Table 2). In these
series, ORR has ranged from 50% to 67%, and CR
from15% to 62%. Importantly, the aGVHDgrade dis-
tribution (proportion of grade III/IV of 88% and 71%,
respectively, in Patriarca et al. [60] and Pidala et al. [61]
compared to 19% in Couriel et al. [59] in these series
differs, and complete remission significantly differs ac-
cording to aGVHDgrade at time of salvage.Other pre-
dictors of CR identified in Patriarca et al. [60] including
age\35, predominance of intestinal involvement, and
time from HCT to Infliximab, are not supported by
the other series. The number of Infliximab doses, for
which the optimal approach is not established, varies
across these series, and does not appear to significantly
affect the likelihood of achieving CR in 1 series [61].
Reported OS ranges from 6% to 38%, and is predicted
by response to salvage therapy with Infliximab [60,61].
Etanercept, a fusion protein comprised of the
extracellular ligand binding component of the
TNF receptor fused with the Fc portion of human
IgG1, has also demonstrated activity in refractory
aGVHD [62].
Chemotherapeutic and Immunomodulatory
Agents
Mycophenolate mofetil
The active metabolite of mycophenolate mofetil
(MMF), mycophenolic acid, inhibits de novo synthesis
of purines in lymphocytes. MMF has been demon-
strated to have activity in GVHD prophylaxis, primary
therapy of aGVHD in combination with glucocorti-
coids [63], as well as in salvage of glucocorticoid-
refractory aGVHD and chronic GVHD (cGVHD).
However, a recent trial did not support benefit in the
addition of MMF to glucocorticoids for the primary
therapy of cGVHD [64]. The literature to date exam-
ining its activity in glucocorticoid-refractory aGVHDconsists of retrospective series [65-67] and small
prospective trials [68-70]. MMF has been generally
well tolerated; the most common adverse effects
include gastrointestinal effects and infrequently dose
limiting cytopenias. Overall responses have been
reported in the range of 31% to 67%, with CRs of
15% to 31%. At follow-up of 2 to 3 years, OS
approaches 33% to 40% (Table 3).
Sirolimus
Sirolimus, a macrolide antibiotic, exerts its immu-
nosuppressive effect through inhibition of mTOR, or
mammalian target of rapamycin, and by downstream
effects that include inhibition of transcription and de-
creased kinase activity of cyclin enzymes involved in
cell cycle progression; other postulated effects in-
clude inhibition of dendritic cell development and
function, blockade of CD28-mediated costimulatory
signaling on effector T cells, and regulatory T cell ex-
pansion, proliferation, and survival. In a pilot study,
Benito et al. [71] reported encouraging activity
(ORR 57%, CR 24%), but toxicity was limiting: 10
subjects did not complete the 14-day course because
of progression or toxicity including myelosuppression
and seizure. Two retrospective series have followed,
which demonstrated more encouraging results
[72,73]. Importantly, the treatment approach in
these 2 series differ from Benito et al. [71]; rather
than a fixed treatment period of 14 days, these studies
involved loading and then indefinite courses of ther-
apy targeted to therapeutic serum levels. ORRs
ranged from 76% to 91%, and CR from 44% to
86%. Comparable CR rates have been observed
across organs involved and grade of aGVHD at sal-
vage. Importantly, therapeutic levels of sirolimus
have been achieved with oral dosing, including cases
with gastrointestinal (GI) involvement. The disparity
in CR rates across these 3 studies may in part be ex-
plained by the aGVHD grade distribution at salvage
therapy: the reported CR rate was 24% in Benito
et al. [71] (grade III/IV 81%) versus 44% in Hoda
et al. [73] (grade III/IV 48%). Ghez et al. [72], how-
ever, reported a CR rate of 86%, despite their sample
being comprised of 73% grade III/IV; interpretation
of the true effect of sirolimus in this series is difficult,
however, as sirolimus was given as a first salvage ther-
apy after 2 mg/kg/day glucocorticoids in 1 patient,
but after 1 prior salvage in 10, 2 prior salvage agents
in 8, and .2 prior salvage therapies in 2 patients.
Adverse effects have consistently included hyper-
lipidemia, cytopenias, and, used in concert with cal-
cineurin inhibitors, thrombotic microangiopathy
(TMA); this has been reported at rates of 24% in Be-
nito et al. [71], 21% in Hoda et al. [73], and 36% in
Ghez et al. [72]. Reported 1-year OS has ranged from
41% to 44%. Achievement of CR of refractory
aGVHD significantly predicted OS (Table 3).
Table 2. Antitumor Necrosis Factor alpha (TNFa) Therapy
Agent Study Methods n Refractory Definition Treatment
Overall
Response
Complete
Response CR by Organ CR by Grade Overall Survival
Predictors
of CR
Predictors
of OS
Infliximab Couriel et al.,
2004
Retrospective
analysis
21 no change in the stage
of skin GVHD after 1
week of 2 mg/kg per
day; progression of
acute GVHD of skin
GVHD or lack of
response of visceral
(liver, GI) GVHD
despite treatment
with 2 mg/kg per for
at least 72 hours;
progression of visceral
GVHD despite
treatment with 2 mg/
kg per day for at least
48 hours; or visceral
GVHD progressing to
stage 4 after 24 hours
of 2 mg/kg per day
10 mg/kg
infliximab
once weekly
for at least
4 doses
(median, 4;
range, 2-9)
ORR: 67%
(by 7 days)
CR: 62% Skin: 6/10 (60%)
GI: 8/12 (67%)
Liver: 1/4 (25%)
At median f/u of
21 months:
OS: 38%
Patriarca
et al.,
2004
Retrospective
analysis
32 acute GVHD $ grade
II without response
after 7 days of $2
mg/kg of steroids
10 mg/kg/day
i.v. weekly
median of 3
courses (range
2-8)
ORR: 59%
(by 7 days)
CR: 19% Responsive to
infliximab: at
median of
630 days, OS
68%
Nonresponsive:
all 13 died,
median 43
days from
onset of
aGVHD
Age <35,
Predominant
intestinal
involvement,
Longer time
from HCT to
infliximab
Response to
infliximab
Pidala et al.,
2009
Retrospective
analysis
52 grade progression
within 3 days, or
failure to achieve
grade improvement
within 5 days after
the initiation of
steroid therapy
10 mg/kg/day
i.v. weekly
(median, 3;
range, 1 to 4)
ORR: 50% CR: 15%
(defined by
sustained
response >1
month)
Skin: 5/15 (33%)
GI: 15/47 (32%)
Liver: 2/5 (40%)
II 5/15
III 2/17
IV 1/20
Median OS:
1.68 months
aGVHD grade
at salvage
Achievement
of CR with
infliximab
Etanercept Busca et al.,
2007
Retrospective
analysis
13 Progression or no
improvement after
6 days of 2 mg/kg
steroids
25 mg was given
subcutaneously twice
weekly for 4 weeks
followed by 25 mg
weekly for 4 weeks
ORR: 6/13
(46%)
CR: 4/13 (31%)
(response
within 8
weeks of
etanercept
therapy)
Skin: 3/8
(37.5%)
GI: 6/11 (55%)
Liver: 2/4 (50%)
II 4 (67%)
III 1 (17%)
IV none
Median
follow-up
317 days:
OS 69%
aGVHD indicates acute graft-versus-host disease; OS, overall survival; CR, complete response; ORR, overall response rate; GI, gastrointestinal.
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Table 3. Chemotherapeutic and Immunomodulatory Agents
Agent Study Methods n Refractory Definition Treatment Overall Response
Complete
Response CR by Organ
CR by
Grade Overall Survival
Predictors
of CR
Predictors
of OS
Mycophenolate
mofetil
Kim et al.,
2004
Prospective
trial
13 Refractory to steroids 2
mg/kg/day for a week
1.5 to 2 g daily ORR: 4/13 (31%) CR: 2/13 (15%) 2 yr OS: 33%
Krejci et al.,
2005
Retrospective
analysis
10 not responding to a
first-line regimen of
cyclosporine A and
steroids 2 mg/kg for
at least 7 days
2 g daily ORR: 6/10 (60%) None achieved
CR
None
achieved CR
None
achieved
CR
Median f/u 27 months:
7/10 of aGVHD
group alive
Baudard et al.,
2002
Retrospective
analysis
6 included steroid-
resistant, and steroid-
or cyclosporine-
intolerant aGVHD
2 g daily ORR: 4/6 (67%) 2/6 alive
Pidala et al.,
2009
Retrospective
analysis
27 grade progression within
3 days, or failure to
achieve grade
improvement over 5
days after initiation of
steroid therapy
1 to 1.5g BID ORR: 59% CR: 7/27 (26%)
(defined by
sustained
response > 1
month)
Skin: 3/13 (23%)
GI: 6/22 (27%)
Liver: 1/6 (17%)
I 1/3
II 5/12
III 0/5
IV 1/7
3yr OS: 40% grade at
salvage,
achievement
of CR
Takami et al.,
2006
Prospective
trial
6 Refractory to
glucocorticoids
ORR: 4/6 (67%) Median f/u 18 months:
OS 64% (overall
sample of 6
refractory aGVHD
and 5 refractory
cGVHD)
Furlong et al.,
2009
Prospective
trial
19
(prospective)
+ 29
(retrospective)
worsened after 3 days
of primary therapy,
showed no
improvement after 7
days or persisted for
more than 14 days
1-1.5 g b.i.d. x 35 days
(continued beyond
35 days if PR or
recurrent aGVHD)
Prospective:
ORR: 9/19 (47%)
Retrospective:
ORR: 14/29 (48%)
(best response
after MMF
therapy)
Prospective:
CR: 6/19 (31%)
Retrospective:
CR: 9/29 (31%)
Prospective:
1 year OS: 16%
Retrospective:
1 year OS: 52%
Sirolimus Benito et al.,
2001
Pilot trial 21 progression after 3 days,
no change after 7
days, or incomplete
response after 14
days after 2mg/kg/day
steroids
(N 5 4) loading dose
(15 mg/m2) of oral
sirolimus on day 1,
then 5 mg/m2/day
for 13 days (n5 17)
either 5 (n5 7) or 4
(n 5 10) mg/m2/day
for 14 days without
loading dose
ORR: 12/21 (57%)
(response at
day 14)
CR: 5/21 (24%) Overall survival 400-
907 days after
HSCT: 33%
Hoda et al.,
2009
Retrospective
analysis
34 grade progression within
3 days or failure to
achieve at least one
grade improvement
over 5 days after
initiation of steroids
loading dose in 19
(56%) patients,
median dose of 6 mg
(range: 3-8)
maintenance dose
of 1-2 mg/day
adjusted to target
therapeutic levels
of 4-12 ng/mL
ORR: 76% CR: 44% (defined
by sustained
response > 1
month)
Skin: 4/13 (31%)
GI: 12/27 (44%)
Liver: 2/4 (50%)
I/II 9/18 (50%)
III 4/8 (50%)
IV 2/8 (25%)
1-year OS: 44% CR of
aGVHD
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Pentostatin (deoxycoformycin) is a nucleoside an-
alog that inhibits adenosine deaminase, leading to the
accumulation of 20-deoxyadenosine 50-trispohsphate
(dATP). This, in turn, leads to decreased IL-2 respon-
siveness and production, and lymphocyte apoptosis.
Bolanos-Meade et al. [74] examined this agent in
a phase I trial (Table 3). Importantly, many had addi-
tional aGVHD therapies prior to pentostatin (cyclo-
sporine in 23, tacrolimus in 17, psoralen plus
ultraviolet-A irradiation for at least 1 month in 2, my-
cophenolate mofetil for at least 3 weeks in 7, daclizu-
mab  at least 4 doses in 5, and ATG in 4). ORR
was 77%, and CR was achieved in 63%; responses var-
ied according to organ involvement and aGVHD
grade. Median survival was 85 days, with deaths pri-
marily from refractory GVHD, infectious etiology,
or multiorgan failure.
Thalidomide
With rationale based on its immunomodulatory
activity and preclinical data supporting its efficacy in
aGVHD, thalidomide has been utilized as a salvage
therapy for glucocorticoid refractory aGVHD
(Table 3). In a retrospective series of aGVHD (grade
III, n5 11; grade IV, n5 10) of diverse organ involve-
ment refractory to high-dose steroids as well as several
additional prior salvage therapies (murine anti-IL2
receptor antibody, n 5 5; azothioprine, n 52; cam-
path, n 5 2; methotrexate, n 5 2; total lymphoid irra-
diation, n 5 1; and ATG, n 5 1), thalidomide did not
induce remission in any patient. All died of refractory
aGVHD at a median of 69 days (range: 23-118) after
transplant [75]. Conversely, the agent does appear to
have activity in refractory cGVHD.Extracorporeal Photochemotherapy (ECP)
ECP involves treatment with 8-methoxypsoralen,
exposure of peripheral blood cells to UV-A light, and
then reinfusion of such cells to patients. It is thought
to mitigate GVHD through effects on APC activation,
alteration toward Th2 cytokine production, and in-
creased regulatoryT cells. In the treatment of glucocor-
ticoid-refractory aGVHD, encouraging responses have
been reported (Table 4). ECP is primarily well toler-
ated, with adverse events including most commonly cy-
topenias thatmay require blood and platelet transfusion
support, and rare occurrences of fever, hypotension, in-
fectious complications, and abdominal pain. In 1 series,
ECP was uniformly the primary salvage therapy [76],
whereas others include those previously treated with
additional salvage agents [77,78]. Responses, most
commonly reported by 3 months of ECP therapy,
include ORR of 67% to 75%, and CR rate of 52% to
60%. There are conflicting data among these trials
regarding organ-specific response: all have reported
Table 4. Extracorporeal photochemotherapy (ECP)
Agent Study Methods n Refractory Definition Treatment
Overall
Response
Complete
Response CR by Organ CR by Grade Overall Survival
Predictors
of CR
Predictors
of OS
ECP Greinix et al.,
2000
Pilot study 21 no response of organ
manifestations or inability
totaper steroids without
increased GVHD activity
with $2 mg/kg steroids x
at least 7 days
treated on 2
consecutive days
(one cycle) at 1-
to 2-week
intervals until
improvement
and thereafter
every 2 to 4
weeks until
maximal
response
ORR: 67%
(by 3
months)
CR: 60% Skin: 12/20
(60%)
Liver: 8/12
(67%)
GI: 0/4 (0%)
II 9/9 (100%)
III 2/3 (67%)
IV 1/8 (12%)
Median follow up
25 months:
OS 57%
CR to ECP
Perfetti et al.,
2008
Retrospective
analysis
23 lack of improvement after
steroids 2–5 mg/kg/day
for $7 days (or steroid
dependent in 4 cases)
cycle (2 treatments
on consecutive
days) every week
for first month,
a cycle every 2
weeks for
following 2
months and
a cycle every
month until
complete
resolution or
stabilization of
GVHD
CR: 12/23
(52%)
(by 90 days)
Skin: 66%
Liver: 27%
GI: 40%
II 70%
III 42%
IV 0%
Median follow-up
37 months:
OS: 48%
Messina et al.,
2003
Retrospective
analysis
33 lack of stable clinical
improvement after 2-5
mg/kg/day steroid for at
least 7 days
2 consecutive days
at 1-week
intervals for the
first month,
every 2 weeks
during the
second and third
month, and then
at monthly
intervals for at
least 3 further
months
ORR: 25/33
(75%)
(by end of
treatment;
median 8
cycles,
range 2-20)
CR: 18/33
(54%)
Skin: 76%
Liver: 60%
GI: 75%
I 2/2 (100%)
II 6/11 (55%)
III 8/13 (62%)
IV 2/7 (29%)
5-yr OS:
Responders: 69%
Nonresponders:
12%
response
to ECP
OS indicates overall survival; CR, complete response; yr, year; GVHD, graft-versus-host disease; GI, gastrointestinal; ORR, overall response rate.
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Biol Blood Marrow Transplant 16:1504-1518, 2010 1515Glucocorticoid-Refractory Acute Graft-versus-Host Diseaseresponse in skin (CR 60%-76%) and liver (CR 27%-
67%), but CR rates in GI involvement were 0% in 1
series [76] compared to 40% to 75% in the others
[77,78]. All support a dependence on overall aGVHD
grade, with diminishing CR rates according to
escalating aGVHD grade. Best response to ECP has
been reported at 2 months of therapy.
Combination Therapy
The overall limited CR rates to salvage therapy in
refractory aGVHD have prompted investigators to at-
tempt combination therapy (Table 5). Kennedy et al.
[79] retrospectively examined outcomes of 16 cases
of refractory aGVHD, where combination therapy
(ATG, substitution of tacrolimus for prior cyclospor-
ine, etanercept 6 MMF) resulted in an ORR of 81%
and CR rate of 69%. Refractory aGVHD deaths, in-
fection (31% infectious death), the occurrence of
TMA (36%), and relapse appeared comparable to out-
comes in a historic series of 20 patients treated with
ATG and tacrolimus. The increased response rates
were associated with a nonsignificant increase in OS
compared with the historic ATG1 tacrolimus cohort.
In a series of pediatric patients treated with allogeneic
HCT for a variety of malignant and nonmalignant
disorders, Rao et al. [80] utilized the combination of
daclizumab and infliximab for the salvage of glucocor-
ticoid refractory aGVHD. Impressive responses were
achieved, with an ORR of 86%, a CR of 63%, and
comparable responses across organs involved. At a me-
dian follow-up of 31 months, OS was 68%. As well,
there did not appear to be an increased risk of infection
with the combined therapy. Although the experience
with combined salvage therapy for refractory aGVHD
is limited and heterogeneous in approach, these early
data suggest that a combined approach may offer im-
proved response rates without increased toxicity or
risk of death because of infectious complications or
primary disease relapse. However, whether combined
therapy will offer a consistent survival advantage over
single salvage agents, as well as the optimal combina-
tion of salvage agents remains to be determined
through further investigation.T
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CCONCLUSIONS AND FUTURE DIRECTIONS
aGVHD remains the major source of transplant-
related morbidity and mortality. Primary therapy
with glucocorticoids achieves complete remission of
aGVHD in the minority of those affected, and there
are few established clinical predictors of response to
glucocorticoids. Failure of primary therapy results in
a large burden of refractory aGVHD. Although the
strength of current evidence is limited, salvage agents
demonstrate activity in the treatment of refractory
aGVHD, but outcomes remain poor. Progress will de-
pend on both rigorous study of salvage therapy for
1516 Biol Blood Marrow Transplant 16:1504-1518, 2010J. Pidala and C. Anasettirefractory aGVHD, as well as insight into the biology
of steroid refractoriness.
In regard to studies examining salvage therapy for
refractory aGVHD, the following major challenges
will need to be addressed: first, standardization of glu-
cocorticoid refractoriness definitions would facilitate
comparisons across studies. A unifying definition
based on themajority of studies represented here could
include the following: progression of at least 1 overall
grade within 3 days, failure to demonstrate any overall
grade improvement over 5 to 7 days, or incomplete re-
sponse by 14 days of 1 to 2 mg/kg/day of glucocorti-
coid therapy. Next, consensus on the time allotted to
determine best response to individual therapies is
needed. Importantly, comparative studies are needed
to guide the rational selection of salvage therapy, and
consideration needs to be given to the most appropri-
ate efficacy endpoints in comparative trials. In addi-
tion, although early results to date suggest that
varied approaches to combined therapies produce en-
couraging response rates and do not appear to lead
to excess toxicity, infectious complications, or relapse,
further investigation is needed to corroborate these
findings, and to determine an optimal salvage regimen.
Progress will also depend on both insights into the
biology of steroid refractoriness in the treatment of
aGVHD, and also the translation of this understand-
ing to novel therapeutic approaches. Although investi-
gation in allied steroid-resistant conditions has
elucidated mechanisms of glucocorticoid refractori-
ness and identified potential means for reversing this
resistance, this has not yet been pursued in aGVHD.
Applications of such work could include the following:
first, gene expression profiling of HCT recipients’
PBMC at diagnosis of aGVHD could be used to de-
velop a classifier for the clinical outcome of glucocor-
ticoid-refractoriness versus responsiveness. This could
provide both a diagnostic and prognostic tool to guide
therapy of aGVHD.With the development of an accu-
rate gene expression classifier, those predicted to have
glucocorticoid-responsive aGVHD could be treated
with glucocorticoids safely, and avoid the potential in-
creased toxicity and risk incurred with additional,
combined immunosuppression as has been explored
in a recent CTN trial [63]. Conversely, those predicted
to have refractory aGVHD could be treated with
a risk-adapted approach utilizing earlier, escalated
therapy that may offer improved outcomes. As well,
the aforementioned molecular insights invoke the pos-
sibility of utilizing therapies aimed at reversing specific
mechanisms of glucocorticoid resistance, several of
which are already available [14]. Used in combination
with glucocorticoids as first-line therapy, refractory
aGVHD could potentially be avoided. In the setting
of salvage therapy, such agents could potentially
reverse glucocorticoid resistance, and improve upon
outcomes seen with currently available salvageagents. These potential approaches require further
investigation.
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